Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Tecovirimat for smallpox infections.

Bolken TC, Hruby DE.

Drugs Today (Barc). 2010 Feb;46(2):109-17. doi: 10.1358/dot.2010.46.2.1437244.

PMID:
20393639
2.

Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection.

Duraffour S, Andrei G, Snoeck R.

IDrugs. 2010 Mar;13(3):181-91. Review.

PMID:
20191435
3.

Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).

Mucker EM, Goff AJ, Shamblin JD, Grosenbach DW, Damon IK, Mehal JM, Holman RC, Carroll D, Gallardo N, Olson VA, Clemmons CJ, Hudson P, Hruby DE.

Antimicrob Agents Chemother. 2013 Dec;57(12):6246-53. doi: 10.1128/AAC.00977-13. Epub 2013 Oct 7.

4.

Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.

Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, Karem K, Damon IK, Byrd CM, Bolken TC, Jordan R, Hruby D.

Antimicrob Agents Chemother. 2009 Jun;53(6):2620-5. doi: 10.1128/AAC.00021-09. Epub 2009 Apr 6.

5.

Molecule of the month. Tecovirimat.

[No authors listed]

Drug News Perspect. 2008 Nov;21(9):517. No abstract available.

PMID:
19180269
6.

Discovery and development of antiviral drugs for biodefense: experience of a small biotechnology company.

Bolken TC, Hruby DE.

Antiviral Res. 2008 Jan;77(1):1-5. Epub 2007 Aug 15. Review.

7.

Mismatched double-stranded RNA: polyI:polyC12U.

[No authors listed]

Drugs R D. 2004;5(5):297-304.

PMID:
15357629
8.

Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.

Berhanu A, Prigge JT, Silvera PM, Honeychurch KM, Hruby DE, Grosenbach DW.

Antimicrob Agents Chemother. 2015 Jul;59(7):4296-300. doi: 10.1128/AAC.00208-15. Epub 2015 Apr 20.

9.

Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.

Leeds JM, Fenneteau F, Gosselin NH, Mouksassi MS, Kassir N, Marier JF, Chen Y, Grosenbach D, Frimm AE, Honeychurch KM, Chinsangaram J, Tyavanagimatt SR, Hruby DE, Jordan R.

Antimicrob Agents Chemother. 2013 Mar;57(3):1136-43. doi: 10.1128/AAC.00959-12. Epub 2012 Dec 17.

10.

An update on the development of drugs against smallpox.

Tse-Dinh YC.

Curr Opin Investig Drugs. 2008 Aug;9(8):865-70. Review.

PMID:
18666034
11.

ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.

Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, Johnson W, Chapman J, Twenhafel N, Tyavanagimatt S, Amantana A, Chinsangaram J, Hruby DE, Huggins J.

Antimicrob Agents Chemother. 2009 May;53(5):1817-22. doi: 10.1128/AAC.01596-08. Epub 2009 Feb 17.

12.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
13.

Smallpox antiviral drug development: satisfying the animal efficacy rule.

Jordan R, Hruby D.

Expert Rev Anti Infect Ther. 2006 Apr;4(2):277-89. Review.

PMID:
16597208
14.

Modeling the Effect of Herd Immunity and Contagiousness in Mitigating a Smallpox Outbreak.

Graeden E, Fielding R, Steinhouse KE, Rubin IN.

Med Decis Making. 2015 Jul;35(5):648-59. doi: 10.1177/0272989X14561681. Epub 2014 Dec 5.

PMID:
25480757
15.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
16.

Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.

[No authors listed]

BioDrugs. 2003;17(1):69-72.

PMID:
12534322
17.

Anticancer Drug Development: The Way Forward.

Connors T.

Oncologist. 1996;1(3):180-181.

18.

Countermeasures to the bioterrorist threat of smallpox.

Jahrling PB, Fritz EA, Hensley LE.

Curr Mol Med. 2005 Dec;5(8):817-26. Review.

PMID:
16375715
19.

Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model.

Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, Hruby DE, Jordan R.

Antiviral Res. 2008 Aug;79(2):121-7. doi: 10.1016/j.antiviral.2008.03.005. Epub 2008 Apr 23.

PMID:
18479761
20.

ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.

Berhanu A, King DS, Mosier S, Jordan R, Jones KF, Hruby DE, Grosenbach DW.

Antimicrob Agents Chemother. 2009 Dec;53(12):4999-5009. doi: 10.1128/AAC.00678-09. Epub 2009 Sep 14.

Supplemental Content

Support Center